Pyxis Oncology, Inc. (PYXS) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 7 Buy, 2 Hold.
The consensus price target is $6.67 (low: $5.00, high: $8.00), representing an upside of 292.4% from the current price $1.70.
Analysts estimate Earnings Per Share (EPS) of $-1.09 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.32 vs est $-1.09 (missed -20.9%). 2025: actual $-1.28 vs est $-1.33 (beat +4.1%). Analyst accuracy: 89%.
PYXS Stock — 12-Month Price Forecast
$6.67
▲ +292.35% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Pyxis Oncology, Inc., the average price target is $6.67, with a high forecast of $8.00, and a low forecast of $5.00.
The average price target represents a +292.35% change from the last price of $1.70.
Highest Price Target
$8.00
Average Price Target
$6.67
Lowest Price Target
$5.00
PYXS Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Pyxis Oncology, Inc. in the past 3 months
EPS Estimates — PYXS
89%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.32
vs Est –$1.09
▼ 17.3% off
2025
Actual –$1.28
vs Est –$1.33
▲ 4.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — PYXS
60%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.016B
vs Est $0.016B
▲ 0.2% off
2025
Actual $0.014B
vs Est $0.003B
▲ 79.5% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
